

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO.: 05015.0366U4	SERIAL NO.	Unassigned 10/675, 960
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Buchanan <i>et al.</i>	CONFIRMATION NO. Unassigned
		FILING DATE: 09/22/2003	GROUP: Unassigned 1623

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	C L A S S	SUBCLASS	FILING DATE IF APPROPRIATE
LCM	A1	6,046,177	04/04/2000	Stella, <i>et al.</i>	—	—	
LCM	A2	6,019,988	02/01/2000	Parab, <i>et al.</i>	—	—	
LCM	A3	6,010,715	01/04/2000	Wick, <i>et al.</i>	—	—	
LCM	A4	5,980,551	11/09/1999	Summers, <i>et al.</i>	—	—	
LCM	A5	5,904,929	05/18/1999	Uekama, <i>et al.</i>	—	—	
LCM	A6	5,865,792	02/02/1999	Ledger <i>et al.</i>	—	—	
LCM	A7	5,817,332	10/06/1998	Urtti, <i>et al.</i>	—	—	
LCM	A8	5,633,368	05/27/1997	Hirsekorn	—	—	
LCM	A9	5,614,199	03/25/1997	Zmitek, <i>et al.</i>	—	—	
LCM	A10	5,383,928	01/24/1995	Scott, <i>et al.</i>	—	—	
LCM	A11	5,298,496	03/29/1994	Vikmon <i>et al.</i>	—	—	
LCM	A12	4,956,351	09/11/1990	Mesens <i>et al.</i>	—	—	
LCM	A13	4,948,395	08/14/1990	Armstrong	—	—	
LCM	A14	4,727,064	02/23/1988	Pitha	—	—	
LCM	A15	4,722,815	02/02/1988	Shibani	—	—	
LCM	A16	4,670,419	06/02/1987	Uda <i>et al.</i>	—	—	
LCM	A17	4,518,588	05/21/1985	Szejtli <i>et al.</i>	—	—	
LCM	A18	4,073,931	02/14/1978	Akito, <i>et al.</i>	—	—	
LCM	A19	3,459,731	08/05/1969	Gramera <i>et al.</i>	—	—	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	C L A S S	SUBCLASS	FILING DATE IF APPROPRIATE
LCM	A20	WO 98/18610	05/07/1998	PCT	—	—	
LCM	A21	EP 0578231	01/12/1994	Europe	—	—	
LCM	A22	10-045609	02/17/1998	Japan (abstract)	—	—	
LCM	A23	58-108201	09/14/1983	Japan (abstract)	—	—	

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LCM	A24	Bauer <i>et al.</i> "Chemical Stabilization of a Vasoactive S-Nitrosothiol with Cyclodextrins Without Loss of Pharmacologic Activity," <i>Pharm. Res.</i> , 8(10):1329-1334, 1991
LCM	A25	Bertele <i>et al.</i> "Prostanoids for Chronic Critical Leg Ischemia - A Randomized, Controlled, Open-Label Trial with Prostaglandin E <sub>1</sub> ," <i>Ann Intern Med.</i> , 130:412-421 (1999)
LCM	A26	Caplus abstract document number 98:40477 (1983)

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LCM	A27	French <i>et al.</i> "Studies on the Schardinger Dextrins. The Preparation and Solubility Characteristics of Alpha, Beta and Gamma Dextrins <sup>1</sup> ," <i>JACS</i> , 71:353-356 (1949)
LCM	A28	Freudenberg <i>et al.</i> "Schardinger's Dextrins Derived from Starch," <i>Chem. Ind.</i> , 731-735 (November 29, 1947)
LCM	A29	Freudenberg <i>et al.</i> "Ober Schardingers Dextine aus Starke," <i>Annalea</i> , 518:102-108 (1935)
LCM	A30	Fucile <i>et al.</i> "Inclusion Complex of Isosorbide-5-mononitrate in $\beta$ -Cyclodextrin: Comparison of Preparation Methods and Assessment of Analytical Techniques," <i>Eur. J. Pharm. Biopharm.</i> , 38(4):140-144 (1992)
LCM	A31	Harata. "X-Ray Structure of Hexakis (2,3,6-tri-O-acetyl)- $\alpha$ -cyclodextrin," <i>Chem. Ltrs.</i> , 589-590 (1998)
LCM	A32	Hirayama <i>et al.</i> "Characterization of Peracylated $\beta$ -Cyclodextrins with Different Chain Lengths as a Novel Sustained Release Carrier for Water-Soluble Drugs," <i>Chem. Pharm. Bull.</i> , 43(1):130-136 (1995)
LCM	A33	Hirayama <i>et al.</i> "Utilization of Diethyl- $\beta$ -Cyclodextrin as a Sustained-Release Carrier for Isosorbide Dinitrate," <i>J. Pharm. Sci.</i> , 77(3):233-236 (March 1988)
LCM	A34	Hirayama <i>et al.</i> , "Release control of 16, 16-dimethyl-trans-delta2-prostaglandin E1 methyl ester by cyclodextrin complexation," <i>Kobunshi Ronbunshu</i> , 39(10):643-648 (1982)
LCM	A35	Idzu <i>et al.</i> "Stability and Bioequivalency of Sublingual Tablet of Nitroglycerin - $\beta$ -cyclodextrin Co-complex," <i>Jpn. J. Hosp. Pharm.</i> , 15(1):36-42 (1989)(Abstract)
LCM	A36	Matsubara <i>et al.</i> "Controlled Release of the LHRH Agonist Buserelin Acetate from Injectable suspensions Containing Triacetylated Cyclodextrins in an Oil Vehicle," <i>J. Controlled Rel.</i> , 31:173-180 (1994)
LCM	A37	Nakanishi <i>et al.</i> "Sustained Release of Flufenamic Acid from a Drug-Triacetyl- $\beta$ -Cyclodextrin Complex," <i>Biol. Pharm. Bull.</i> , 20(1):66-70 (1997)
LCM	A38	Soliman <i>et al.</i> "Controlled Release of Diltiazem by a Combination of Short-and Long-chain Peracylated $\beta$ -Cyclodextrins in Dogs," <i>Pharm. Sci.</i> , 2:533-536 (1996)
LCM	A39	Stadler-Szoke <i>et al.</i> "A nitroglycerin $\beta$ -cyclodextrin zarvanykomplex," <i>Acta Pharmaceutica Hungarica</i> , 49:30-34 (1979)
LCM	A40	<i>not present</i> Szejtli, "Chemistry, Physical and Biological Properties of Cyclodextrins," pp. 5-40 (date unknown)
LCM	A41	Tomono <i>et al.</i> "Effect of $\beta$ -Cyclodextrins on Sustained Release of Nitroglycerin from Ointment Bases," <i>Yakuzaigaku</i> , 51(1):22-28 (1991) (Abstract)
LCM	A42	Tomono <i>et al.</i> "Interaction of Nitroglycerin with 6-O- $\alpha$ -maltosylcyclomaltoheptaose," <i>Carb. Res.</i> , 192:351-356 (1989)
LCM	A43	Tomono <i>et al.</i> "Complexation of Nitroglycerin with Several $\beta$ -Cyclodextrin Polymers by Grinding Method," <i>Yakuzaigaku</i> , 48(1):9-16 (1988) (Abstract)
LCM	A44	Uekama <i>et al.</i> "Peracylated $\beta$ -Cyclodextrins as Novel Sustained-release Carriers for a Water-soluble Drug, Molsidomine" <i>J. Pharm. Pharmacol.</i> , 46:714-717 (1994)
LCM	A45	Uekama <i>et al.</i> "Stabilization of isosorbide 5-mononitrate in solid state by $\beta$ -cyclodextrin complexation," <i>Int'l. J. Pharm.</i> , 25:339-346 (1985)
LCM	A46	Uekama <i>et al.</i> "Improvement of Dissolution Characteristics and Chemical Stability of Prostaglandin E <sub>1</sub> by Y-Cyclodextrin Complexation," <i>Chem. Pharm. Bull.</i> , 32(1):275-279 (1984)
LCM	A47	Umemura <i>et al.</i> "Effect of Diethyl- $\beta$ -Cyclodextrin on the Release of Nitroglycerin from Formulations," <i>Drug Des. Del.</i> , 6:297-310 (1990)
LCM	A48	Yamamoto <i>et al.</i> "Improvement of Stability and Dissolution of Prostaglandin E by Maltosyl- $\beta$ -Cyclodextrin in Lyophilized Formulation," <i>Chem. Pharm. Bull.</i> , 40(3):747-751 (1992)

EXAMINER: Leigh C. Maier DATE CONSIDERED: 7/14/86

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.